Janssen Pharmaceuticals has paired up with Ichor Medical Systems to develop and market DNA-based vaccine products to treat chronic hepatitis B. The partners will use the startup's TriGrid electroporation technology for clinical administration of a DNA vaccine.
A Dutch immuno-oncology player that has received venture funding from Johnson & Johnson, Novartis and Pfizer is preparing to list on Nasdaq. The company--Merus--hopes to raise upward of €100 million ($107 million) to advance its pipeline of bispecific IgG antibodies into the clinic and through early-phase trials.
Johnson & Johnson's Ethicon division received clearance from the FDA for an expanded indication of its Evarrest patch, which can now be used to help control bleeding during adult liver surgery.
Why didn't Johnson & Johnson buy Pharmacyclics? Good question--and one The Wall Street Journal posed to CEO Alex Gorsky in a recent interview in Tokyo.
Johnson & Johnson's consumer division knows that much of its target audience consists of millennials, Hispanics and moms--and that those three groups have something else in common, too: soccer.
GlaxoSmithKline and Johnson & Johnson have settled a short-lived legal spat over GSK's allergy drug marketing claims--meaning that now, the only battle left will be the one for market share.
Johnson & Johnson and Google have partnered to create new robotic-assisted surgical platforms. The deal is the latest example of Google working with a major life sciences company to make a significant technological advance.
Johnson & Johnson has a Chinese strategy: long-term thinking. Despite an economic slowdown and regulatory crackdowns--and the example of other multinationals that have scaled back there--CEO Alex Gorsky figures it's worth it to ride out the storm.
Royal Philips and Janssen Pharmaceutical have partnered in a multiyear deal to create a hand-held, blood-based diagnostic for brain disorders. The test will be based on a product that Philips is already developing, the Minicare system. The financial details of the partnership were undisclosed.
Newcomers showed off at this year's American Academy of Dermatology meeting, with more than one touting Stelara-beating data--and prepping the market for an all-out psoriasis war.